Strides Arcolab receives ANDA approval

New Delhi, Apr 24 (UNI) Bangalore-based Strides Arcolab Ltd today said it has received two Abbreviated New Drug Application (ANDA) approvals for Ondansetron Injection USP, two mg/ml in 20 ml and two ml vials.

The product is licensed to Akorn-Strides, LLC, which is a joint venture of Akorn and Stride Arcolab Ltd.

''These approvals reflect yet another significant milestone for the Akorn-Strides partnership which now has approvals for five sterile injectable products and plans for commercialisation are underway,'' Strides Arcolab Vice Chairman and Group CEO Arun Kumar said in a statement.

UNI SR SG PM1655